$88.36
Closed
-(-)
At close
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply
About
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 68 full-time employees. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
Key stats
Open
$88.70
Volume
2.11M
Market cap
$7.88B
Prev. close
$89.05
Impl / hst vl
-
Open interest
$0.00
$88.32
Day’s Range
$88.81
$69.81
52W Range
$147.98
Valuation
33
Valuation score
Overvalued
P/E
-
P/S
-
P/B
19.23
Current ratio
5.97
Debt / Equity
-
ROE
-107.83%
Gross margin
-
Income growth
242.29%
FCF growth
5.62
Analysts estimates
Consensus rating
Strong buy
The average rating from top 6 analysts indicates that stock may significantly outperform the market
Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$174.01
The top 11 analysts forecasts that 12-month price may increase by 96.93%, with a low of $81.07 and a high of $216.72
$81.07
Low
$174.01
Avg
$216.72
High
Current price
Earnings
Q2 ‘26 revenue
$0.00
Q2 ‘26 net income
-$185.55M
Revenue
Net income
Previous EPS
-$2.34
Estimate EPS
$0.00
Actual EPS
Estimate EPS
Explore the Healthcare sector
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply